Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and improves learning and memory in adult mice
Ruxolitinib is the first janus kinase 1 (JAK1) and JAK2 inhibitor that was approved by the United States Food and Drug Administration (FDA) agency for the treatment of myeloproliferative neoplasms. The drug targets the JAK/STAT signalling pathway, which is critical in regulating the gliogenesis proc...
Main Authors: | Abdullah, M.A (Author), Cheah, P.-S (Author), Habib, O. (Author), Hamzah, H. (Author), Hassan, Z. (Author), Lee, H.-C (Author), Leong, M.P.-Y (Author), Lim, S.-M (Author), Ling, K.-H (Author), Md Yusof, H. (Author), Mohd Moklas, M.A (Author), Nordin, N. (Author), Seth, E.A (Author), Vidyadaran, S. (Author), Zainal Abidin, S. (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Research
2021
|
Series: | Scientific Reports
|
Online Access: | View Fulltext in Publisher View in Scopus |
Similar Items
-
Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and improves learning and memory in adult mice
by: Abdullah, MA, et al.
Published: (2021) -
Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and improves learning and memory in adult mice
by: Han-Chung Lee, et al.
Published: (2021-02-01) -
Astrogenesis versus astrogliosis
by: Andrew O Koob
Published: (2017-01-01) -
Leptin potentiates astrogenesis in the developing hypothalamus
by: Daniele M. Rottkamp, et al.
Published: (2015-11-01) -
Adult Astrogenesis and the Etiology of Cortical Neurodegeneration
by: Tal C. Mohn, et al.
Published: (2015-11-01)